On April 23, 2026 Exicure, Inc. (Nasdaq: XCUR) reported that it has entered into a co-development agreement with Adbiotech Co., Ltd. (KOSDAQ: 179530), a Korea-based biotechnology company, to explore combination therapies based on Burixafor (GPC-100) across multiple therapeutic areas.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The collaboration will focus on evaluating combination strategies involving Burixafor (GPC-100) in indications including sickle cell disease (SCD), acute myeloid leukemia (AML), and solid tumors.
Under the agreement, Adbiotech will conduct in vivo studies and support preclinical validation and translational research, while Exicure will provide Burixafor and lead clinical and regulatory strategy.
Burixafor successfully completed a Phase 2 clinical trial in multiple myeloma last year, providing a foundation for further evaluation in hematologic indications such as AML and SCD. Based on its clinical profile to date, Burixafor may have potential applicability in additional hematologic indications.
The parties intend to conduct in vivo validation studies and, subject to further agreement, may advance selected programs into IND-enabling studies and clinical trials. The parties also intend to secure funding to support the advancement of future clinical development.
Further details regarding development plans, budget, intellectual property, and commercialization will be determined in a subsequent definitive agreement.
A representative of Exicure commented, "This agreement represents an important step in expanding the evaluation of Burixafor in combination approaches across multiple indications."
(Press release, Exicure, APR 23, 2026, View Source [SID1234664745])